The estimated Net Worth of Nicholas Donoghoe is at least $15 Milione dollars as of 20 March 2024. Nicholas Donoghoe owns over 21,082 units of Abbvie Inc stock worth over $10,878,165 and over the last 6 years he sold ABBV stock worth over $4,167,301. In addition, he makes $0 as Senior Vice President - Enterprise Innovation at Abbvie Inc.
Nicholas has made over 3 trades of the Abbvie Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 21,082 units of ABBV stock worth $3,716,757 on 20 March 2024.
The largest trade he's ever made was selling 21,082 units of Abbvie Inc stock on 20 March 2024 worth over $3,716,757. On average, Nicholas trades about 3,152 units every 167 days since 2019. As of 20 March 2024 he still owns at least 55,903 units of Abbvie Inc stock.
You can see the complete history of Nicholas Donoghoe stock trades at the bottom of the page.
Dr. Nicholas Donoghoe, M.D., is the Senior Vice President - Enterprise Innovation of the Company. He previously served as a Partner at McKinsey & Company, leading the firm's West Coast pharma and biotechnology practice. Dr. Donoghoe joined the firm in 2007 and supported multiple successful launches in therapeutic areas such as oncology, immunology, and primary care. He joined AbbVie in 2019.
Nicholas Donoghoe is 38, he's been the Senior Vice President - Enterprise Innovation of Abbvie Inc since 2019. There are 32 older and no younger executives at Abbvie Inc. The oldest executive at Abbvie Inc is Edward Liddy, 73, who is the Independent Director.
Nicholas's mailing address filed with the SEC is North Waukegan Road, North Chicago, Lake County, Illinois, 60044, United States.
Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell e Glenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
Abbvie Inc executives and other stock owners filed with the SEC include: